Her scientific interests lie mostly in Surgery, Radiation therapy, Lung cancer, Internal medicine and Cancer. As a member of one scientific family, Andrea Bezjak mostly works in the field of Surgery, focusing on Neoadjuvant therapy and, on occasion, Sarcoma, Soft tissue sarcoma, Randomization and Adjuvant therapy. Her Radiation therapy research incorporates themes from Prospective cohort study and Effective dose, Nuclear medicine.
Her studies in Lung cancer integrate themes in fields like Survival rate, Supine position, Brachial plexus and Radiography. The Internal medicine study combines topics in areas such as Gastroenterology and Oncology. Her Cancer research is multidisciplinary, relying on both Quality of life and Clinical trial.
Her main research concerns Lung cancer, Internal medicine, Radiation therapy, Radiology and Oncology. She combines subjects such as Locally advanced, Medical physics, Chemoradiotherapy and Radiation treatment planning with her study of Lung cancer. Andrea Bezjak works mostly in the field of Internal medicine, limiting it down to topics relating to Surgery and, in certain cases, Clinical trial, as a part of the same area of interest.
Her Radiation therapy research is multidisciplinary, incorporating perspectives in Stage, Prospective cohort study and Nuclear medicine. Her research integrates issues of Tomography and Cone beam ct in her study of Nuclear medicine. Her Lung research extends to Radiology, which is thematically connected.
Internal medicine, Lung cancer, Radiology, Oncology and Non small cell are her primary areas of study. Her work deals with themes such as Gastroenterology and Surgery, which intersect with Internal medicine. Her Lung cancer research is multidisciplinary, incorporating elements of Stage, Chemoradiotherapy, Radiation therapy and Nuclear medicine.
Her Radiation therapy research includes themes of Clinical trial and Intensive care medicine. Her Radiology study integrates concerns from other disciplines, such as Esophagus and Lung. The study incorporates disciplines such as Palliative radiotherapy, Palliative Radiation Therapy and Carcinoma in addition to Oncology.
Her primary areas of investigation include Internal medicine, Lung cancer, Oncology, Esophagus and Prospective cohort study. Her Internal medicine study frequently draws connections to other fields, such as Surgery. She interconnects Chemoradiotherapy, Radiology, Nuclear medicine and Lung in the investigation of issues within Lung cancer.
In the subject of general Oncology, her work in non-small cell lung cancer is often linked to State, thereby combining diverse domains of study. In her study, Gastroenterology, Radiosurgery, Cohort and Pulmonary artery is inextricably linked to Toxicity, which falls within the broad field of Esophagus. In her research on the topic of Performance status, Survival rate and Cancer is strongly related with Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd;José Rodrigues Pereira;Tudor Ciuleanu;Eng Huat Tan.
The New England Journal of Medicine (2005)
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman;Rebecca Paulus;James Galvin;Jeffrey Michalski.
Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases
Jackson Sai-Yiu Wu;Rebecca Wong;Mary Johnston;Andrea Bezjak.
International Journal of Radiation Oncology Biology Physics (2003)
Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial
Christina A. Meyers;Jennifer A. Smith;Andrea Bezjak;Minesh P. Mehta.
Journal of Clinical Oncology (2004)
Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases
Minesh P. Mehta;Patrick Rodrigus;C. H J Terhaard;Aroor Rao.
Journal of Clinical Oncology (2003)
Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Andrea Bezjak;Dongsheng Tu;Lesley Seymour;Gary Clark.
Journal of Clinical Oncology (2006)
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
F. A. Shepherd;J. Pereira;T. E. Ciuleanu;E. H. Tan.
Journal of Clinical Oncology (2004)
Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verification, and intrafraction tumor position.
Thomas G. Purdie;Jean Pierre Bissonnette;Kevin Franks;Andrea Bezjak.
International Journal of Radiation Oncology Biology Physics (2007)
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn;Michael Snee;Linda Ashcroft;Wiebke Appel.
Lancet Oncology (2017)
Interpreting clinically significant changes in patient-reported outcomes.
Jolie Ringash;Brian O'Sullivan;Andrea Bezjak;Donald A. Redelmeier.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: